The Value of Tailored Therapy on Survival in High Risk MDS with Del5q: Report of an Unusual Case
Open Access
- 14 February 2023
- journal article
- research article
- Published by Gavin Publishers in Annals of Case Reports
- Vol. 8 (1)
Abstract
Interstitial deletions of chromosome 5q [del (5q)] are the most common cytogenetic abnormality in myelodysplastic syndrome (MDS), accounting for 10-15% of cases [1-3]. The most common breakpoint for (cancel: myelodysplastic syndrome; replacing for: MDS) MDS cases with isolated del (5q) is del (5) (q13q33) [4]. MDS with isolated del (5q) is associated with a relatively favourable prognosis and typical features, which include macrocytic anaemia, thrombocytosis, and the presence of hypolobated megakaryocytes [5]. When this cytogenetic finding occurs in high risk MDS or acute myeloid leukaemia, it is associated with an unfavourable outcome [1]. Treatment approaches differ according to the prognosis with an indication for lenalidomide for low risk MDS with isolated del (5q) [3, 6-8] and a common indication for azacitidine for high risk MDS [3,9], independent of karyotype. The clinical results in higher risk del (5q) MDS by lenalidomide, alone or in combination with azacitidine [10], are still limited [1,11]. In the present case, we report the sequential treatment with azacitidine followed by lenalidomide, upon clearance of bone marrow (BM) blasts that was not planned at the initial treatment stage but as the result of a tailored decision making which took into account the haematological status after six cycles of hypomethylating agent and the patient’s preferences.Keywords
This publication has 12 references indexed in Scilit:
- Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomideBlood Cancer Journal, 2022
- Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemiaHistopathology, 2022
- Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?Expert Review of Hematology, 2020
- Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q)Laboratory Investigation, 2019
- A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemiaHematology, 2019
- SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5qClinical Lymphoma Myeloma and Leukemia, 2018
- A decade of progress in myelodysplastic syndrome with chromosome 5q deletionLeukemia, 2018
- Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceCancer Medicine, 2015
- Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real‐world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemiaEuropean Journal of Haematology, 2015
- Revised International Prognostic Scoring System for Myelodysplastic SyndromesBlood, 2012